Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Ramanathan · SciRah

Researcher profile · Semantic Scholar

R. Ramanathan

Share profile

R. Ramanathan — researcher profile on SciRah

h-index: 69
Works: 397
Citations: 26K

Most-cited papers

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
M. Javle, M. Lowery, R. Shroff, K. Weiss +25 more
2017Journal of Clinical Oncology580 citations Open access
Semantic Scholar
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
W. Tap, Z. Wainberg, S. Anthony, P. Ibrahim +36 more
2015New England Journal of Medicine482 citations
Semantic Scholar
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
R. Shroff, M. Javle, Lianchun Xiao, A. Kaseb +9 more
2019JAMA Oncology439 citations Open access
Semantic Scholar
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
J. de Bono, R. Ramanathan, L. Mina, R. Chugh +12 more
2017Cancer Discovery373 citations Open access
Semantic Scholar
Hepatocytes direct the formation of a pro-metastatic niche in the liver.
Jae W. Lee, M. Stone, P. Porrett, Stacy K. Thomas +25 more
2019Nature336 citations Open access
Semantic Scholar
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
D. Sohal, Pamela B. Mangu, A. Khorana, M. Shah +11 more
2016Journal of Clinical Oncology285 citations Open access
Semantic Scholar
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
D. Sohal, E. Kennedy, A. Khorana, M. Copur +13 more
2018Journal of Clinical Oncology239 citations Open access
Semantic Scholar
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
D. V. Von Hoff, M. Mita, R. Ramanathan, G. Weiss +10 more
2016Clinical Cancer Research239 citations Open access
Semantic Scholar
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik, L. Appleman, A. Tolcher, K. Papadopoulos +17 more
2016Annals of Oncology217 citations Open access
Semantic Scholar
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
A. De Jesus-Acosta, E. Sugar, P. O'Dwyer, R. Ramanathan +13 more
2019British Journal of Cancer164 citations Open access
Semantic Scholar
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
R. Ramanathan, R. Korn, N. Raghunand, J. Sachdev +11 more
2017Clinical Cancer Research148 citations Open access
Semantic Scholar
Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
D. Juric, I. Krop, R. Ramanathan, T. Wilson +11 more
2017Cancer Discovery141 citations Open access
Semantic Scholar
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
J. Tabernero, E. Chiorean, J. Infante, S. Hingorani +9 more
2015The Oncologist136 citations Open access
Semantic Scholar
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
S. Moschos, R. Sullivan, W. Hwu, R. Ramanathan +24 more
2018JCI Insight128 citations Open access
Semantic Scholar
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
M. Barrett, K. Anderson, E. Lenkiewicz, M. Andreozzi +8 more
2015OncoTarget127 citations Open access
Semantic Scholar
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort
H. Burris, Suzanne J. Bakewell, J. Bendell, J. Infante +6 more
2016ESMO Open125 citations Open access
Semantic Scholar
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
J. Strickler, C. Weekes, J. Nemunaitis, R. Ramanathan +11 more
2018Journal of Clinical Oncology113 citations Open access
Semantic Scholar
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E. Chiorean, D. V. Von Hoff, M. Reni, F. Arena +13 more
2016Annals of Oncology103 citations Open access
Semantic Scholar
Immunotherapy in pancreatic cancer treatment: a new frontier
K. Thind, Leslie J. Padrnos, R. Ramanathan, M. Borad
2017Therapeutic Advances in Gastroenterology77 citations Open access
Semantic Scholar
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial.
G. Jameson, E. Borazanci, H. Babiker, E. Poplin +12 more
2020JAMA Oncology76 citations Open access
Semantic Scholar
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
J. Infante, R. Korn, L. Rosen, P. LoRusso +9 more
2017British Journal of Cancer73 citations Open access
Semantic Scholar
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
P. Kasi, D. Kotani, M. Cecchini, K. Shitara +5 more
2016BMC Cancer71 citations Open access
Semantic Scholar
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
D. Mahalingam, M. Patel, J. Sachdev, L. Hart +7 more
2020British Journal of Clinical Pharmacology62 citations Open access
Semantic Scholar
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
W. Scheithauer, R. Ramanathan, M. Moore, T. Macarulla +7 more
2016Journal of Gastrointestinal Oncology62 citations Open access
Semantic Scholar
Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
E. Borazanci, S. Millis, J. Kimbrough, N. Doll +2 more
2017Journal of Gastrointestinal Oncology50 citations Open access
Semantic Scholar
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
V. Gorbunova, J. Beck, R. Hofheinz, P. García-Alfonso +10 more
2018British Journal of Cancer49 citations Open access
Semantic Scholar
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
D. Goldstein, D. V. Von Hoff, M. Moore, E. Greeno +7 more
2016European Journal of Cancer49 citations Open access
Semantic Scholar
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
R. Ramanathan, D. V. Von Hoff, F. Eskens, G. Blumenschein +7 more
2020Targeted oncology45 citations Open access
Semantic Scholar
A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).
M. Demeure, T. Armaghany, S. Ejadi, R. Ramanathan +13 more
201644 citations
Semantic Scholar
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
G. Weiss, G. Jameson, D. V. Von Hoff, B. Valsasina +9 more
2018Investigational new drugs42 citations
Semantic Scholar
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)
G. Dietsch, T. D. Randall, R. Gottardo, D. Northfelt +6 more
2015Clinical Cancer Research36 citations Open access
Semantic Scholar
Second‐line treatment in patients with pancreatic ductal adenocarcinoma: A meta‐analysis
M. Sonbol, Belal M. Firwana, Zhen Wang, Diana Almader-Douglas +5 more
2017Cancer32 citations Open access
Semantic Scholar
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
M. Barrett, R. Deiotte, E. Lenkiewicz, S. Malasi +12 more
2017British Journal of Cancer32 citations Open access
Semantic Scholar
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers
M. Borad, J. Egan, Rachel M. Condjella, W. Liang +33 more
2016Scientific Reports30 citations Open access
Semantic Scholar
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
V. Picozzi, R. Ramanathan, M. Lowery, A. Ocean +27 more
2015European Journal of Cancer28 citations Open access
Semantic Scholar
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
J. Berlin, R. Ramanathan, J. Strickler, Deepa S. Subramaniam +11 more
2018British Journal of Cancer27 citations Open access
Semantic Scholar
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Gina Song, T. Tarrant, Taylor F. White, D. Barrow +8 more
2015Nanomedicine : nanotechnology, biology, and medicine25 citations
Semantic Scholar
Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
Yoon-Koo Kang, P. LoRusso, R. Salgia, Jui-Yen Chia +8 more
201525 citations
Semantic Scholar
Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
D. Ahn, R. Ramanathan, T. Bekaii-Saab
2018Cancers24 citations Open access
Semantic Scholar
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
T. Deleon, D. Ahn, J. Bogenberger, P. Anastasiadis +8 more
2018Future Oncology24 citations
Semantic Scholar
A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).
R. Ramanathan, Shannon L. McDonough, P. Philip, S. Hingorani +11 more
201824 citations
Semantic Scholar
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine
V. Kunzmann, R. Ramanathan, D. Goldstein, Helen Liu +4 more
2016Pancreas22 citations Open access
Semantic Scholar
Phase 1 study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors
E. Lam, S. Eckhardt, W. Messersmith, A. Jimeno +13 more
2017Molecular Cancer Therapeutics21 citations Open access
Semantic Scholar
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
J. Strickler, P. LoRusso, R. Salgia, Yoon-Koo Kang +11 more
2020Molecular Cancer Therapeutics19 citations Open access
Semantic Scholar
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer
R. Ramanathan, G. Thomas, A. Khorana, Satish Shah +5 more
2019Oncology19 citations Open access
Semantic Scholar
A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
G. Jameson, E. Borazanci, H. Babiker, E. Poplin +11 more
201719 citations
Semantic Scholar
A phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine (NAPPCG) in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma.
E. Borazanci, G. Jameson, M. Borad, R. Ramanathan +5 more
201715 citations
Semantic Scholar
A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs).
R. Shroff, M. Borad, Lianchun Xiao, A. Kaseb +9 more
201713 citations
Semantic Scholar
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
M. Gordon, J. Nemunaitis, M. Barve, Z. Wainberg +11 more
2021Molecular Cancer Therapeutics11 citations Open access
Semantic Scholar
CA 19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial ( MPACT ) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E. Chiorean, D. V. Von Hoff, M. Reni, F. Arena +13 more
201611 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. V. Von Hoff×22
Invite
D. V. Von Hoff — researcher profile on SciRah
M. Borad×10
Invite
M. Borad — researcher profile on SciRah
T. Bekaii-Saab×6
Invite
T. Bekaii-Saab — researcher profile on SciRah
G. Weiss×6
Invite
G. Weiss — researcher profile on SciRah

×6

Invite

G. Jameson — researcher profile on SciRah

D. Goldstein×6

Invite

D. Goldstein — researcher profile on SciRah

Invite

D. Ahn — researcher profile on SciRah

Invite

J. Sachdev — researcher profile on SciRah

Invite

R. Korn — researcher profile on SciRah

Invite

J. Infante — researcher profile on SciRah

J. Strickler×5

Invite

J. Strickler — researcher profile on SciRah

Invite

P. LoRusso — researcher profile on SciRah